Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Immunogen, Inc. (NasdaqNM:IMGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 16Earnings Announcement
Location
128 Sidney Street
Cambridge, MA 02139
Phone: (617) 995-2500
Fax: (617) 995-2510
Employees (last reported count): 60
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 10%
·Institutional: 41% (45% of float)
(162 institutions)
·Net Inst. Buying: 931.0K shares (+5.58%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Immunogen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates are tumor-activated prodrugs (TAPs). They are based on the Company's proprietary technology platform, which combines monoclonal antibodies that target tumor cells, and potent drugs. Together with partners, the Company is currently developing two TAP product candidates. The Company has also initiated a licensing program that allows it to generate cash flow through granting rights to other companies to use portions of its TAP technology in their product development programs. The Company can use this revenue from technology licenses to support research to identify new targets for TAPs and fund research and development of internal TAP products, which the Company may commercialize on its own or with partners.
More from Market Guide: Expanded Business Description

Financial Summary
Immunogen develops, produces, and markets commercial anti-cancer and other biopharmaceutical products based on molecular immunology. For the fiscal year ended 6/01, revenues fell 60% to $4.5 million. Net loss before accounting change rose from $237 thousand to $9.6 million. Revenues reflect lower collaboration payments received under the SmithKline Beecham agreement. Net loss also reflects higher research and development costs related to Phase I cancer product huC242-DM1/SB-408075.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 525; after tax earnings were -3,277. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Mitchel Sayare, Ph.D., 52
Chairman, Pres, CEO
$333K
Gregg Beloff
CFO, VP
--  
Walter Blattler, Ph.D., 51
Exec. VP - Science and Technology, Treasurer, Director
265K
John Lambert, Ph.D., 49
Sr. VP, Pharmaceutical Devel.
184K
Pauline Ryan, 33
VP-Bus. Devel.
142K
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:IMGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$8.875
Recent Price$13.58 
52-Week High
on 8-Nov-2000
$45.50 
Beta0.72 
Daily Volume (3-month avg)316.0K
Daily Volume (10-day avg)151.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-21.3%
52-Week Change
relative to S&P500
+5.6%
Share-Related Items
Market Capitalization$523.3M
Shares Outstanding38.5M
Float34.7M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$3.90 
Earnings (ttm)-$0.29 
Earnings (mrq)-$0.09 
Sales (ttm)$0.10 
Cash (mrq*)$2.87 
Valuation Ratios
Price/Book (mrq*)3.48 
Price/EarningsN/A 
Price/Sales (ttm)134.10 
Income Statements
Sales (ttm)$3.66M
EBITDA (ttm*)-$9.97M
Income available to common (ttm)-$10.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-10.90%
Return on Equity (ttm)-11.91%
Financial Strength
Current Ratio (mrq*)32.80 
Debt/Equity (mrq*)0 
Total Cash (mrq)$150.8M
Short Interest
As of 8-Aug-2001
Shares Short902.0K
Percent of Float2.6%
Shares Short
(Prior Month)
1.07M
Short Ratio2.73 
Daily Volume331.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.